Journal
FUTURE ONCOLOGY
Volume 6, Issue 6, Pages 1031-1042Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.10.40
Keywords
base excision repair; camptothecin; FHA; forkhead-associated domain; inhibitor; ionizing radiation; polynucleotide kinase; single strand break repair; XRCC1
Categories
Funding
- North West Cancer Research Fund
- Dowager Countess Eleanor Peel Trust
Ask authors/readers for more resources
Pharmacological inhibition of DNA-repair pathways as an approach for the potentiation of chemo- and radio-therapeutic cancer treatments has attracted increasing levels of interest in recent years. Inhibitors of several enzymes involved in the repair of DNA strand breaks are currently at various stages of the drug development process. Polynucleotide kinase (PNK), a bifunctional DNA-repair enzyme that possesses both 3'-phosphatase and 5'-kinase activities, plays an important role in the repair of both single strand and double strand breaks and as a result, RNAi-mediated knockdown of PNK sensitizes cells to a range of DNA-damaging agents. Recently, a small molecule inhibitor of PNK has been developed that is able to sensitize cells to ionizing radiation and the topoisomerase I poison, camptothecin, Although still in the early stages of development, PNK inhibition represents a promising means of enhancing the efficacy of existing cancer treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available